Navigation Links
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Date:7/12/2011

kine-mediated inflammatory signaling cascade. Sarilumab was developed using Regeneron VelocImmune® antibody technology.  

About the MOBILITY TrialThe MOBILITY trial is a randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of sarilumab on top of MTX in patients with active RA who are inadequate responders to MTX therapy.  The primary objective of part A of the dose ranging MOBILITY trial was to demonstrate that sarilumab on top of MTX is effective in reducing the signs and symptoms of RA at 12 weeks.  The five doses tested were 100 milligrams (mg) and 150 mg every week and 100 mg, 150 mg and 200 mg every other week.  The primary objective of part B of the MOBILITY trial will be to demonstrate that sarilumab on top of MTX is effective in reducing the signs and symptoms of RA at 24 weeks.  Further details about the MOBILITY trial are available at http://clinicaltrials.gov/ct2/results?term=SAR+153191+mobility.

About Rheumatoid ArthritisRheumatoid arthritis (RA) is a chronic systemic autoimmune disease affecting approximately 0.5%–1% of the global adult population.  Abnormal immune response causes an inflamed, thickened synovium, the membrane that lines the joint.  As synovitis expands, the inflammatory process can damage the bone and cartilage of the joint and the surrounding tissues.  RA-related inflammation can involve the heart and the lung.  In 10% of patients with RA the liver is affected. Complications of RA include anemia and leucopenia.  At times RA can be very painful and affect a person's ability to carry out everyday tasks.  Most people with RA experience periods when their symptoms worsen (flares or active disease) separated by periods in which the symptoms improve.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
2. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
3. Sanofi Pasteur Commends Winners of International BioGENEius Challenge
4. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
5. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
8. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
9. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
10. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
11. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of ... transformation in the pain market, according to a ... Inc., a firm providing market research and consultation ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... change for hydrocodone combination products from Schedule III ...
(Date:10/22/2014)... Oct. 22, 2014   Reproductive Medicine Associates ... in the field of infertility, presents new clinical ... screening. The research abstract, released during the 70 ... (ASRM) meeting in Honolulu, Hawaii ... gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... UPI ), a medical device company that develops, ... announced today that David Kaysen, President and CEO, and Medi ... strategy and financial results at the Sixth Annual JMP Securities ... 2011 at The St. Regis Hotel in New York. ...
... Reportlinker.com announces that a new market research report is ... The Global Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... The global generics market is estimated at about $225 ... the value of the total global generics sector will ...
Cached Medicine Technology:Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:10/25/2014)... 2014 Background: , In 1998 Bob ... is a pioneer in the field of establishing recovery community ... treatment system and when he retired, he set out to ... public service. , 1. Where are the ... them? , 2. Can the recovery community be organized ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... ... ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’. ... ... of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced ...
... fewer attacks per year, save millions in health costs, ... If all states banned smoking in restaurants, offices and ... from heart attacks would drop by more than 18,000 ... bans have been implemented in some states, but not ...
... explanation for the difference, study says , THURSDAY, May ... common form of stroke has decreased significantly among whites ... new regional survey designed to be representative of the ... Greater Cincinnati/Northern Kentucky Stroke Study showed an overall drop ...
... from The University of Texas MD Anderson Children,s Cancer Hospital ... patients increased the survival of children with rare tumors in ... issue of the Journal of Pediatric Surgery , looked ... aggressive pediatric cancer known as desmoplastic small round cell tumor ...
... Montreal, May 20, 2010 The results of a ... by Dr. Jean-Claude Tardif are now available in the journal ... of the MHI Research Centre, as well as a professor in ... at the Universit de Montral. The promising findings of ...
... ... Association (NRPA) is reminding Americans to take the proper steps to ensure that their local ... Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) May ...
Cached Medicine News:Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 2Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 3Health News:Big Decline in Heart Attacks If All States Had Smoking Bans 2Health News:Stroke Incidence Down, But Not for Blacks 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: